文献速递肺栓塞与肺血管病

1990-2021年全球肺动脉高压疾病负担的系统分析

Global, regional, and national burden of pulmonary arterial hypertension, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
PubMed 文献 · Lancet Respir Med · 2024-10-18

本研究基于全球疾病负担研究(GBD)2021方法,将肺动脉高压(PAH)作为独立病因,利用流行病学与生命登记数据估算1990-2021年204个国家和地区的非致死性与致死性负担。

要点

  • 女性占62%,诊断集中于女性和老年人

核心结论

  • PAH是一种罕见但致命的疾病,在全球范围内造成相当大的健康负担。
  • PAH在女性和老年人中被不成比例地诊断。

研究设计与样本

  • 基于GBD 2021方法,将PAH作为独立死因和残疾原因,使用流行病学与生命登记数据建模。
  • 估算1990-2021年204个国家和地区的非致死性与致死性PAH负担,仅纳入第1组肺动脉高压,不含第2-5组。

临床怎么用

  • 提示临床关注女性和老年人群的PAH筛查与诊断。
  • 可将PAH负担与慢性髓性白血病、多发性硬化、克罗恩病等疾病相参照理解。
  • 为呼吸科医生认识PAH全球流行病学及资源配置提供依据。

局限性

  • 仅纳入第1组肺动脉高压,未包含第2-5组肺动脉高压。
  • 原文未报告具体的建模局限说明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pulmonary arterial hypertension (PAH) is a vascular disease characterised by restricted flow and high pressure through the pulmonary arteries, leading to progressive right heart failure and death. This study reports the global burden of PAH, leveraging all available data and using methodology of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) to understand the epidemiology of this under-researched and morbid disease. METHODS: Prior to the current effort, the burden of PAH was included in GBD as a non-specific contributor to "other cardiovascular and circulatory disease" burden. In this study, PAH was distinguished as its own cause of death and disability in GBD, producing comparable and consistent estimates of PAH burden. We used epidemiological and vital registry data to estimate the non-fatal and fatal burden of PAH in 204 countries and territories from 1990 to 2021 using standard GBD modelling approaches. We specifically focused on PAH (group 1 pulmonary hypertension), and did not include pulmonary hypertension groups 2-5. FINDINGS: In 2021, there were an estimated 192 000 (95% uncertainty interval [UI] 155 000-236 000) prevalent cases of PAH globally. Of these, 119 000 (95 900-146 000) were in females (62%) and 73 100 (58 900-89 600) in males (38%). The age-standardised prevalence was 2·28 cases per 100 000 population (95% UI 1·85-2·80). Prevalence increased with age such that the highest prevalence was among individuals aged 75-79 years. In 2021, there were 22 000 deaths (18 200-25 400) attributed to PAH globally, with an age-standardised mortality rate of 0·27 deaths from PAH per 100 000 population (0·23-0·32). The burden of disease appears to be improving over time (38·2% improvement in age-standardised years of life lost [YLLs] in 2021 relative to 1990). YLLs attributed to PAH were similar to estimates for conditions such as chronic myeloid leukaemia, multiple sclerosis, and Crohn's disease. INTERPRETATION: PAH is a rare but fatal disease that accounts for a considerable health-associated burden worldwide. PAH is disproportionally diagnosed among females and older adults. FUNDING: Cardiovascular Medical Research and Education Fund and the Bill & Melinda Gates Foundation.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Global, regional, and national burden of pulmonary arterial hypertension, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Respir Med. 2024. PMID: 39433052. doi:10.1016/S2213-2600(24)00295-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。